Evidence Hub

Two Patients With Resistant Immune Thrombocytopenic Purpura and Portal Hypertension Treated Safely With Laparoscopic Splenectomy: A Case Series Report and Literature Review

Mujtaba O. K. Mohamed, A. Alhillan, I. Patel, Arman Mushtaq, E. Zurkovsky, Christian Kaunzinger, M. Hossain

Journal of Current Surgery, 2019

Abstract

Immune thrombocytopenia (previously called idiopathic thrombocytopenic purpura (ITP)) is characterized by an autoimmune destruction and clearance of platelets and megakaryocytes by reticuloendothelial system including liver and spleen. Most of the time, it occurs in the absence of any obvious stimulus. Secondary immune thrombocytopenia coexists with an underlying disease such as human immunodeficiency virus (HIV), hepatitis C virus (HCV), chronic lymphocytic leukemia (CLL), systemic lupus erythematosus (SLE), or can occur following exposure to certain drugs such as heparin or quinidine. Medical treatment includes corticosteroids, intravenous immunoglobulins and rituximab. Splenectomy is reserved for patients who fail medical therapy. Laparoscopic splenectomy is safer than open splenectomy. The main surgical complication of splenectomy is intra-abdominal bleeding. Additional risk factors for post-operative bleeding such as portal hypertension can alter treatment decision in regard to splenectomy. J Curr Surg. 2019;9(4):61-65 doi: https://doi.org/10.14740/jcs399

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free